The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs).
 
Laurence Albiges
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Peloton therapeutics (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Manuela Schmidinger
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD Oncology; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD Oncology; Pfizer; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Naila Taguieva Pioger
Employment - Ipsen
 
David Pérol
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Lilly; Novartis; Roche
Research Funding - MSD Avenir
Travel, Accommodations, Expenses - AstraZeneca
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; MSD
Honoraria - Ars tempi; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; COCS GmbH; Eisai; EUSA Pharma; Exelixis; Ipsen; Janssen-Cilag; Lilly; MedKom Akademie; Merck Serono; MSD Oncology; NewConceptOncology; Novartis; Pfizer; PharmaMar; Promedior; Roche; Update Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Cerulean Pharma; ClinSol; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; MSD Oncology; Novartis; Pfizer